On October 13, 2010, the U.S. Food and Drug Administration (FDA) issued a femur fracture warning informing patients and health care providers about the doable danger of atypical thigh bone (femur) fractures in patients who take bisphosphonates, such as Fosamax.  Bisphosphonates are a class of drugs employed to stop and treat osteoporosis. Atypical femur fractures, a rare but critical kind of thigh bone fracture, have been predominantly reported in patients taking drugs such as Fosamax for longer than five years.

A labeling adjust and Medication Guide for Fosamax, Fosamax Plus D, and their generic merchandise will reflect this latest femur fracture warning by the FDA.
Studies Assistance Femur Fracture Warning

With regard to this femur fracture warning, the FDA stated that it is &ldquocontinuing to evaluate information about the safety and effectiveness of bisphosphonates when employed long-term for osteoporosis therapy.&rdquo &ldquoIn the interim, it&rsquos essential for patients and well being care experts to have all the safety data accessible when determining the very best course of therapy for osteoporosis.&rdquo

These days&rsquos femur fracture warning follows a March 10, 2010 Drug Safety Communication announcing the FDA&rsquos ongoing safety evaluation of bisphosphonate use and the occurrence of atypical femur fractures. The FDA has since reviewed all available data on bisphosphonate use, such as data summarized in the American Society for Bone Mineral Study Task Force report. The report proposed further item labeling, better identification and tracking of patients experiencing these breaks, and far more research to determine whether and how these drugs lead to the significant but uncommon fractures.

Based on the FDA&rsquos review, the Warnings and Precautions section of all bisphosphonate goods for osteoporosis, such as Fosamax, will be revised to contain the femur fracture warning, and the FDA will require the inclusion of the very same femur fracture warning into a Medication Guide to much better inform patients of the achievable increased fracture danger. People who have suffered a femur fracture after taking Fosamax may want to file a fosamax lawsuit.

Given this most current femur fracture warning, the FDA recommends that well being care experts be conscious of the possible danger in patients taking bisphosphonates and contemplate periodic reevaluation of the need to have for continued bisphosphonate therapy for patients who have been on bisphosphonates for longer than 5 years.

Patients taking bisphosphonates must report any new thigh or groin discomfort to their well being care provider and be evaluated for a achievable femur fracture. If you or someone you know have suffered a femur fracture after taking Fosamax contact a fosamax lawyer for help.